Viral Vaccines
Empower your vaccine development with our CDMO services for viral vaccines.
We aim to subdue the high costs of vaccine manufacturing that often prevents a major part of the world population access to these critical products.
Process Development
Scalable, Robust & GMP Compliant.
Optimize your viral vaccine production with our Process Development services.
Our team of experts leverages cutting-edge technologies and processes to support the development and scaling of your vaccine production.
- Upstream Process Development
- Downstream Process Development
- Analytical Development
- In Silico Cost Modeling
Transform your viral vaccine production with our Upstream Process Development services.
Our team of experts utilizes cutting-edge technologies and processes to optimize your vaccine production from the earliest stage. From cell line development and process optimization, to scale-up and technology transfer, we offer a comprehensive solution for your needs. Our goal is to help you achieve maximum yields, product quality, and efficiency in your viral vaccine production.
Unlock the full potential of your viral vaccine with our Analytical Development services.
Our Analytical development experts help to ensure that your vaccine product meets the highest standards for quality, safety, and efficacy. From method development and validation, to release and stability testing, we have got you covered. Trust us to provide the critical data you need to support your vaccine development and bring your product to market with confidence.
Maximize the success of your viral vaccine with our Analytical Development services.
Our expert team uses advanced technologies and procedures to guarantee your vaccine product conforms to the highest quality, safety, and effectiveness standards. From creating and validating methods, to conducting release and stability testing, we offer a complete solution to meet your needs. Rely on us to supply the essential data required to advance your vaccine development and launch your product with confidence.
Accelerate your viral vaccine development with our In Silico Modelling services.
Our team of experts utilizes advanced computational tools and techniques to simulate and predict key aspects of your vaccine production, from process optimization and scale-up, to product formulation and stability. With our In Silico Modelling services, you can save time and resources by predicting and addressing potential challenges before they occur. Trust us to provide valuable insights and support your vaccine development journey.
Manufacturing Solutions
Partner with a leader in viral vaccine CDMO services.
We have extensive experience in manufacturing a wide range of viruses including polio, measles, rubella, influenza and rotavirus.
Your research is only valuable if your data can be reproduced.
We are experienced in growing wildtype and attenuated viruses on mammalian cell lines in adherent, microcarrier-based, or suspension cell culture. Hereto, we have a variety of cell lines at our disposal, such as modified, cloned, or parental Vero, MRC-5, and MDCK cell lines. Using these platforms, we manufacture a wide range of viruses including polio, measles, rubella, influenza and rotavirus.
Our broad experience with viral vaccine production, process development, and assays allows us to deliver a complete package. You receive purified vaccine with the associated biochemical and analytical characterization data. We have successfully delivered various vaccines for preclinical studies, such as hepatitis A, influenza, Sabin polio, Salk polio and RSV.
Bring your viral vaccine to the clinic with confidence using our Clinical Manufacturing services.
We offer a broad range of clinical manufacturing services for inactivated, live-attenuated, and sub-unit viral vaccines.
We have generic protocols available to produce, purify, test, and release measles-, polio-, rubella- and influenza-based vaccine products, as well as specific protocols for each strain. Typically, a clinical manufacturing trajectory starts with the manufacturing of a pre-master virus seed (pre-MVS) under R&D conditions, whereby the designated virus is selected and propagated on the supporting cell line.
We are proud to have delivered vaccine products for phase-I and phase-II clinical studies in both the EU and US markets. Our experience in the field, anchored in production, purification, and testing protocols, has resulted in a successful track record in delivering vaccine products.
Streamline the regulatory journey for your viral vaccine with our Product Release and Regulatory Support services.
Our knowledgeable experts stay up-to-date with the latest regulations and standards, offering unparalleled guidance and support. From preparing regulatory documents, to providing insights on clinical trials and commercialization, we have you covered.
Our manufacturing license and batch release by our inhouse Qualified Person (QP) ensure a smoort release process. and our regulatory experts with a track record in bringing INDs and IMPDs help you secure market approval for your product.
Technologies for Viral Vector Development & Manufacturing
Improve product yield, reduce process development time & increase product stability.
The SCOUT® technology provides for an effective tool for “Design-of-Experiments” approaches. It uses a miniaturized production and purification platform to rapidly develop multivariate processes.
Under the HIP-Vax® brand, we market our process development services and know-how which enables fast and low-cost vaccine manufacturing using bioprocess intensification technologies.
The SATIRN® technology delivers a platform to manufacture potent, self-adjuvating, thermostable, membrane protein-based vaccines.
